1
00:00:00,000 --> 00:00:03,833
Weekly semaglutide lowered BMI by 13.5% in

2
00:00:03,833 --> 00:00:07,867
children aged 6 to under 12.

3
00:00:07,867 --> 00:00:11,000
STEP Young was a phase 3, double-blind trial

4
00:00:11,000 --> 00:00:14,133
of 167 children with obesity, with lifestyle

5
00:00:14,133 --> 00:00:17,300
counselling in both groups.

6
00:00:17,300 --> 00:00:20,333
At week 68, BMI fell by 13.5% with

7
00:00:20,333 --> 00:00:24,967
semaglutide and rose by 2.7% with placebo.

8
00:00:24,967 --> 00:00:28,800
BMI category improved in 79% on semaglutide

9
00:00:28,800 --> 00:00:32,167
versus 23% on placebo.

10
00:00:32,167 --> 00:00:35,200
Gastrointestinal events were most common,

11
00:00:35,200 --> 00:00:38,500
and led 1 child on semaglutide to stop.

12
00:00:38,500 --> 00:00:41,733
The modest trial was funded by Novo Nordisk;

13
00:00:41,733 --> 00:00:44,633
the abstract omits growth and what followed

14
00:00:44,633 --> 00:00:46,533
stopping.

15
00:00:46,533 --> 00:00:49,133
The full report, its source and a free

16
00:00:49,133 --> 00:00:53,267
teaching slide are at diabesityrounds.com.
